PL3047851T3 - Zastosowanie odiparcilu w leczeniu mukopolisacharydozy - Google Patents

Zastosowanie odiparcilu w leczeniu mukopolisacharydozy

Info

Publication number: PL3047851T3
Authority: PL; Poland
Prior art keywords: odiparcil; mucopolysaccharidosis; treatment
Prior art date: 2013-10-04

Application number

PL16159903T

Other languages

English (en)

Inventor

Philippe Masson

Jean-Louis Junien

Original Assignee

Inventiva

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-04

Filing date

2014-10-03

Publication date

2017-10-31

2014-10-03 Application filed by Inventiva filed Critical Inventiva

2017-10-31 Publication of PL3047851T3 publication Critical patent/PL3047851T3/pl

Links

JRHNIQQUVJOPQC-AQNFWKISSA-N 4-methyl-7-[(2r,3r,4s,5s)-3,4,5-trihydroxythian-2-yl]oxychromen-2-one Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1SC[C@@H](O)[C@H](O)[C@H]1O JRHNIQQUVJOPQC-AQNFWKISSA-N 0.000 title 1
208000002678 Mucopolysaccharidoses Diseases 0.000 title 1
206010028093 mucopolysaccharidosis Diseases 0.000 title 1
229950005036 odiparcil Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Detergent Compositions (AREA)
Medicinal Preparation (AREA)

PL16159903T 2013-10-04 2014-10-03 Zastosowanie odiparcilu w leczeniu mukopolisacharydozy PL3047851T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR1359657A FR3011468B1 (fr)	2013-10-04	2013-10-04	Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
EP16159903.0A EP3047851B1 (fr)	2013-10-04	2014-10-03	Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
EP14187588.0A EP2857023B1 (fr)	2013-10-04	2014-10-03	Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose

Publications (1)

Publication Number	Publication Date
PL3047851T3 true PL3047851T3 (pl)	2017-10-31

Family

ID=49876835

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL14187588.0T PL2857023T3 (pl)	2013-10-04	2014-10-03	Zastosowanie odiparcilu w leczeniu mukopolisacharydozy
PL16159903T PL3047851T3 (pl)	2013-10-04	2014-10-03	Zastosowanie odiparcilu w leczeniu mukopolisacharydozy

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL14187588.0T PL2857023T3 (pl)	2013-10-04	2014-10-03	Zastosowanie odiparcilu w leczeniu mukopolisacharydozy

Country Status (27)

Country	Link
US (1)	US9561246B2 (pl)
EP (2)	EP2857023B1 (pl)
JP (2)	JP6412927B2 (pl)
KR (2)	KR102328103B1 (pl)
CN (2)	CN109999049B (pl)
AU (1)	AU2014330977B2 (pl)
BR (1)	BR112016007306B1 (pl)
CA (1)	CA2925567C (pl)
CY (2)	CY1117740T1 (pl)
DK (2)	DK2857023T5 (pl)
EA (1)	EA029370B1 (pl)
ES (2)	ES2633806T3 (pl)
FR (1)	FR3011468B1 (pl)
HR (2)	HRP20160811T1 (pl)
HU (2)	HUE036306T2 (pl)
IL (1)	IL244829A0 (pl)
MA (1)	MA38931B1 (pl)
MX (1)	MX362596B (pl)
MY (1)	MY184721A (pl)
PH (1)	PH12016500541A1 (pl)
PL (2)	PL2857023T3 (pl)
PT (2)	PT2857023T (pl)
RS (2)	RS56235B1 (pl)
SI (2)	SI3047851T1 (pl)
TN (1)	TN2016000111A1 (pl)
UA (1)	UA117934C2 (pl)
WO (1)	WO2015049471A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9982288B2 (en) *	2014-04-30	2018-05-29	The Nemours Foundation	Mucopolysaccharidosis IVA/VII screening and treatment method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0421829T3 (da)	1989-09-22	1995-01-16	Fournier Ind & Sante	Nye benzopyranon-beta-D-thioxylosider, fremgangsmåde til deres fremstilling og deres terapeutiske anvendelse
US6866844B2 (en) *	2002-11-07	2005-03-15	Biomarin Pharmaceutical Inc.	Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
GB0400812D0 (en) *	2004-01-14	2004-02-18	Celltech R&D Ltd	Novel compounds
EP1815206B1 (en) *	2004-10-13	2016-04-06	PTC Therapeutics, Inc.	Compounds for nonsense suppression, and methods for their use
FR2903698B1 (fr) *	2006-07-13	2009-01-30	Fournier S A Sa Lab	Nouveaux derives de 5-thioxylopyranose.
NZ702801A (en) *	2010-06-25	2016-08-26	Shire Human Genetic Therapies	Treatment of sanfilippo syndrome type b

2013
- 2013-10-04 FR FR1359657A patent/FR3011468B1/fr active Active
2014
- 2014-10-03 PL PL14187588.0T patent/PL2857023T3/pl unknown
- 2014-10-03 AU AU2014330977A patent/AU2014330977B2/en active Active
- 2014-10-03 RS RS20170844A patent/RS56235B1/sr unknown
- 2014-10-03 PT PT141875880T patent/PT2857023T/pt unknown
- 2014-10-03 CA CA2925567A patent/CA2925567C/fr active Active
- 2014-10-03 US US14/506,239 patent/US9561246B2/en active Active
- 2014-10-03 SI SI201430342T patent/SI3047851T1/sl unknown
- 2014-10-03 PL PL16159903T patent/PL3047851T3/pl unknown
- 2014-10-03 DK DK14187588.0T patent/DK2857023T5/en active
- 2014-10-03 EA EA201690709A patent/EA029370B1/ru not_active IP Right Cessation
- 2014-10-03 SI SI201430031A patent/SI2857023T1/sl unknown
- 2014-10-03 MX MX2016004333A patent/MX362596B/es active IP Right Grant
- 2014-10-03 RS RS20160504A patent/RS54907B1/sr unknown
- 2014-10-03 KR KR1020167008265A patent/KR102328103B1/ko active Active
- 2014-10-03 EP EP14187588.0A patent/EP2857023B1/fr active Active
- 2014-10-03 HU HUE16159903A patent/HUE036306T2/hu unknown
- 2014-10-03 DK DK16159903.0T patent/DK3047851T3/en active
- 2014-10-03 ES ES16159903.0T patent/ES2633806T3/es active Active
- 2014-10-03 BR BR112016007306-1A patent/BR112016007306B1/pt active IP Right Grant
- 2014-10-03 WO PCT/FR2014/052507 patent/WO2015049471A1/fr not_active Ceased
- 2014-10-03 HU HUE14187588A patent/HUE027787T2/en unknown
- 2014-10-03 TN TN2016000111A patent/TN2016000111A1/fr unknown
- 2014-10-03 MA MA38931A patent/MA38931B1/fr unknown
- 2014-10-03 MY MYPI2016701175A patent/MY184721A/en unknown
- 2014-10-03 CN CN201910022697.5A patent/CN109999049B/zh active Active
- 2014-10-03 EP EP16159903.0A patent/EP3047851B1/fr active Active
- 2014-10-03 ES ES14187588.0T patent/ES2578161T3/es active Active
- 2014-10-03 PT PT161599030T patent/PT3047851T/pt unknown
- 2014-10-03 UA UAA201603536A patent/UA117934C2/uk unknown
- 2014-10-03 CN CN201480053707.7A patent/CN105636597B/zh active Active
- 2014-10-03 KR KR1020217030209A patent/KR102345244B1/ko active Active
- 2014-10-03 JP JP2016519831A patent/JP6412927B2/ja active Active
2016
- 2016-03-21 PH PH12016500541A patent/PH12016500541A1/en unknown
- 2016-03-30 IL IL244829A patent/IL244829A0/en active IP Right Grant
- 2016-07-06 CY CY20161100633T patent/CY1117740T1/el unknown
- 2016-07-07 HR HRP20160811TT patent/HRP20160811T1/hr unknown
2017
- 2017-08-04 CY CY20171100839T patent/CY1119212T1/el unknown
- 2017-08-30 HR HRP20171305TT patent/HRP20171305T1/hr unknown
2018
- 2018-07-31 JP JP2018143573A patent/JP6545334B2/ja active Active

Also Published As

Publication number	Publication date
CN105636597A (zh)	2016-06-01
KR20210119562A (ko)	2021-10-05
EA201690709A1 (ru)	2016-07-29
PT2857023T (pt)	2016-07-11
TN2016000111A1 (fr)	2017-07-05
HUE027787T2 (en)	2016-10-28
JP6412927B2 (ja)	2018-10-24
IL244829A0 (en)	2016-05-31
KR20160058119A (ko)	2016-05-24
ES2633806T3 (es)	2017-09-25
KR102345244B1 (ko)	2021-12-30
BR112016007306B1 (pt)	2022-09-06
HUE036306T2 (hu)	2018-06-28
HRP20171305T1 (hr)	2017-10-20
EP2857023A1 (fr)	2015-04-08
MX362596B (es)	2019-01-25
DK3047851T3 (en)	2017-09-18
JP2016531888A (ja)	2016-10-13
DK2857023T3 (en)	2016-07-25
CA2925567C (fr)	2021-10-05
RS56235B1 (sr)	2017-11-30
AU2014330977A1 (en)	2016-05-19
EP2857023B1 (fr)	2016-04-20
KR102328103B1 (ko)	2021-11-17
MX2016004333A (es)	2016-11-10
FR3011468A1 (fr)	2015-04-10
ES2578161T3 (es)	2016-07-21
JP6545334B2 (ja)	2019-07-17
PH12016500541A1 (en)	2016-06-13
CY1119212T1 (el)	2018-02-14
MY184721A (en)	2021-04-19
EP3047851B1 (fr)	2017-06-14
FR3011468B1 (fr)	2015-12-04
AU2014330977B2 (en)	2019-10-03
PT3047851T (pt)	2017-07-20
CN105636597B (zh)	2019-02-15
MA38931B1 (fr)	2018-09-28
SI2857023T1 (sl)	2016-08-31
EP3047851A1 (fr)	2016-07-27
BR112016007306A2 (pt)	2017-09-12
HK1209033A1 (zh)	2016-06-30
HRP20160811T1 (hr)	2016-09-23
CY1117740T1 (el)	2017-05-17
WO2015049471A1 (fr)	2015-04-09
PL2857023T3 (pl)	2016-09-30
EA029370B1 (ru)	2018-03-30
CN109999049B (zh)	2022-01-25
MA38931A1 (fr)	2018-04-30
CN109999049A (zh)	2019-07-12
DK2857023T5 (en)	2016-08-29
CA2925567A1 (fr)	2015-04-09
US9561246B2 (en)	2017-02-07
UA117934C2 (uk)	2018-10-25
SI3047851T1 (sl)	2017-10-30
US20150099789A1 (en)	2015-04-09
RS54907B1 (sr)	2016-10-31
JP2018162330A (ja)	2018-10-18

Publication	Publication Date	Title
IL246239B (en)	2019-08-29	Bicyclic heterocyclic compounds and their uses in healing
GB201320729D0 (en)	2014-01-08	Therapeutic compounds and their use
SMT202500311T1 (it)	2025-09-12	Aceclidina per uso nel trattamento della presbiopia
SG11201602838UA (en)	2016-05-30	Safe socket and use thereof
IL246221B (en)	2020-04-30	Endazoles and their uses
GB201305277D0 (en)	2013-05-01	Novel combination and use
GB201311361D0 (en)	2013-08-14	Compounds and their therapeutic use
GB2515865B (en)	2017-05-10	Use of galactooligosaccharides in therapy
EP2922536A4 (en)	2016-06-08	USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
GB201304872D0 (en)	2013-05-01	Treatment
IL245272B (en)	2020-11-30	pif-transfected cells and methods of use
GB201307989D0 (en)	2013-06-12	Novel combinations and use
GB201308736D0 (en)	2013-06-26	Compounds and their therapeutic use
GB201308753D0 (en)	2013-06-26	Compounds and their use in therapy
GB201304038D0 (en)	2013-04-17	Treated cells and therapeutic uses
GB201307310D0 (en)	2013-05-29	Treatment
SI3047851T1 (sl)	2017-10-30	Uporaba odiparcila za zdravljenje mukopolisaharidoze
GB201308217D0 (en)	2013-06-12	Compounds and their use in therapy
GB201309498D0 (en)	2013-07-10	Novel diagnosis and therapy
GB2525530B (en)	2018-11-14	Treatment of hard surfaces
GB201317804D0 (en)	2013-11-20	Therapeutic compounds and their use
GB201316173D0 (en)	2013-10-23	Compounds and their therapeutic use
GB201307677D0 (en)	2013-06-12	Compounds and their therapeutic use
GB201308539D0 (en)	2013-06-19	Liquid treatment
GB201322958D0 (en)	2014-02-12	Uses of oligouronates in cancer treatment